Lake Street Downgrades AVITA Medical to Hold, Lowers Price Target to $4
Benzinga Newsdesk 1 year ago
NewsDowngradesPrice TargetAnalyst Ratings
Lake Street analyst Frank Takkinen downgrades AVITA Medical (NASDAQ:RCEL) from Buy to Hold and lowers the price target from $8 to $4.
Lake Street analyst Frank Takkinen downgrades AVITA Medical (NASDAQ:RCEL) from Buy to Hold and lowers the price target from $8 to $4.